Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

CONTEXT: Statistical models employed in analysing patient-level cost and effectiveness data need to be flexible enough to adjust for any imbalanced covariates, account for correlations between key parameters, and accommodate potential skewed distributions of costs and/or effects. We compare prominent statistical models for cost-effectiveness analysis alongside randomised controlled trials (RCTs) and covariate adjustment to assess their performance and accuracy using data from a large RCT. METHOD: Seemingly unrelated regressions, linear regression of net monetary benefits, and Bayesian generalized linear models with various distributional assumptions were used to analyse data from the TASMINH2 trial. Each model adjusted for covariates prognostic of costs and outcomes. RESULTS: Cost-effectiveness results were notably sensitive to model choice. Models assuming normally distributed costs and effects provided a poor fit to the data, and potentially misleading inference. Allowing for a beta distribution captured the true incremental difference in effects and changed the decision as to which treatment is preferable. CONCLUSIONS: Our findings suggest that Bayesian generalized linear models which allow for non-normality in estimation offer an attractive tool for researchers undertaking cost-effectiveness analyses. The flexibility provided by such methods allows the researcher to analyse patient-level data which are not necessarily normally distributed, while at the same time it enables assessing the effect of various baseline covariates on cost-effectiveness results.

Original publication

DOI

10.1007/s10198-015-0731-8

Type

Journal article

Journal

Eur J Health Econ

Publication Date

11/2016

Volume

17

Pages

927 - 938

Keywords

Bayesian regression methods, Cost-effectiveness analysis, Covariate adjustment, Net monetary benefits, Regression methods, Seemingly unrelated regressions, Adult, Aged, Aged, 80 and over, Bayes Theorem, Cost-Benefit Analysis, Female, Humans, Hypertension, Male, Middle Aged, Models, Econometric, Quality-Adjusted Life Years, Randomized Controlled Trials as Topic, Regression Analysis, Self Care, Statistics, Nonparametric, Telemedicine